BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
1394 results:

  • 1. [Mechanism study on the effect of androgen antagonism in prostate cancer].
    Song X; Song Q; Wang R; Zuo QJ; Zhang ZY
    Zhonghua Nan Ke Xue; 2023 May; 29(5):402-408. PubMed ID: 38602755
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.
    Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A
    Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Unveiling the Anticancer Potential of Pasak Bumi (Eurycoma Longifolia Jack) Root Extract in prostate cancer treatment.
    Rahman EY; Kania N; Sutapa H; Purnomo AF; Panghiyangani R; Skripsiana NS
    Med Arch; 2024; 78(2):117-121. PubMed ID: 38566865
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
    PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
    Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
    Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
    Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
    Uzelac M; Xin R; Ongkeko WM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
    Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
    Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells.
    Zhang B; Zhao J; Kang D; Wang Z; Xu L; Zheng R; Liu A
    Chem Biol Drug Des; 2024 Mar; 103(3):e14503. PubMed ID: 38480495
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of akt-mediated survival mechanisms in prostate cancer.
    Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
    Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Capivasertib: First Approval.
    Shirley M
    Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
    Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
    EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
    Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
    BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/akt/mTOR pathway.
    Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
    Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dual targeting of the androgen receptor and PI3K/akt/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
    Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
    Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
    Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
    Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through akt/FOXO signaling pathway.
    Sun D; Guo J; Liang W; Chen Y; Wei S; Li A; Wang L; Chen X
    Med Oncol; 2024 Jan; 41(2):44. PubMed ID: 38170382
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/akt/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents.
    Yu J; Wang X; Cheng S; Zeng X; Wan X; Wei S; Xu B; Luo H; Meng X
    Eur J Pharm Sci; 2024 Jan; 192():106660. PubMed ID: 38052256
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 70.